ArticleThe Journal of clinical endocrinology and metabolism2015
Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: a link between healthy and unhealthy obesity?
Article in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 5 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- Circulating and dietary advanced glycation end products and obesity in an adult population: A paradox of their detrimental effects in obesity.Frontiers in endocrinology · 2022Pooled it
- Circulating Advanced Glycation End Products and Their Soluble Receptors in Relation to All-Cause and Cardiovascular Mortality: A Systematic Review and Meta-analysis of Prospective Observational Studies.Advances in nutrition (Bethesda, Md.) · 2021Pooled it
- The Impact of Low Advanced Glycation End Products Diet on Metabolic Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Advances in nutrition (Bethesda, Md.) · 2021Pooled it
- The impact of low advanced glycation end products diet on obesity and related hormones: a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- The relationship between advanced glycation end products and gestational diabetes: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Advanced glycation end-products regulate extracellular matrix-adipocyte metabolic crosstalk in diabetes.Scientific reports · 2019Trial
- Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2018Trial
- Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial.Diabetologia · 2016Trial
- Serum advanced glycation end-products as a biomarker of cumulative glycaemic burden and complications in type 2 diabetes: a pilot study.Annals of medicine · 2026Article
- Perinatal consumption of a thermally processed diet alters feeding behavior and has sex-dependent effects upon metabolism in later life in mice.Food chemistry. Molecular sciences · 2026Article
- Concentrations of Maillard reaction products and advanced glycation end-products in commercially available extruded dry, retorted wet, and mildly cooked (fresh) cat foods from the United Kingdom and United States.Journal of animal science · 2026Article
- Dietary and Endogenous Advanced Glycation End Product and Breast Carcinogenesis: A Challenging Lack of Association in a Rigorous Case-Control Study.Journal of nutrition and metabolism · 2026Article
- Role of ChREBP-PPARα-FGF21 Axis in Metabolic Dysfunction of MASLD.International journal of molecular sciences · 2025Article
- Are Advanced Glycation End-Products and Skin Autofluorescence Associated with E-Selectin and Pulse Wave Velocity as Markers of Atherosclerosis Risk in Children with Obesity?International journal of molecular sciences · 2025Article
- Mechanism and implications of advanced glycation end products (AGE) and its receptor RAGE axis as crucial mediators linking inflammation and obesity.Molecular biology reports · 2025Review
- Advanced Glycation End Products in Disease Development and Potential Interventions.Antioxidants (Basel, Switzerland) · 2025Review
- Descriptive Epidemiology and Prognostic Significance of Diaphragm Thickness in the General Population: The Nagahama Study.Journal of cachexia, sarcopenia and muscle · 2025Article
- The relationship between advanced glycation end products, metabolic metrics, HbAFrontiers in endocrinology · 2025Article
- Anti-obesity and hepatoprotective effects of pyridoxal phosphate in rats with metabolic syndrome by raising anti-oxidant potential in both serum and liver tissue, while also decreasing hepatic nuclear factor expression.Iranian journal of basic medical sciences · 2025Article
- Impact of high-protein, low-calorie diet on anthropometric indices, glycation, and inflammation associated with the fat mass and obesity (FTO) gene among individuals with overweight/obesity.Frontiers in nutrition · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 3 countries.
Funding
Abstract
contextAlthough obesity can predispose to the metabolic syndrome (MS), diabetes, and cardiovascular disease, not all obese subjects develop MS, hence the need for new indicators of risk for this syndrome. Advanced glycation end products (AGEs) correlate with factors involved in the MS, including inflammation and insulin resistance (IR). Because AGEs can be derived from food and are modifiable, it is important to determine whether they are a risk factor for MS.
objectiveThe objective of this study was to assess the association of endogenous and exogenous AGEs with MS criteria.
designThe following data were collected in a cross-sectional study of subjects with and without the MS: serum AGEs (sAGEs) and mononuclear cell AGEs, metabolites, pro- and antiinflammatory markers, body fat mass measures, including abdominal magnetic resonance imaging, and caloric and dietary AGE (dAGE) consumption.
settingThe study was conducted in the general community.
participantsParticipants included 130 MS and 139 non-MS subjects of both sexes, older than 50 years.
resultssAGEs ((ϵ)N-carboxymethyllysine, methylglyoxal) were markedly elevated in obese persons with more than one other MS criteria but not in obese without MS criteria. sAGEs directly correlated with markers of IR (HOMA) and inflammation (leptin, TNFα, RAGE) and inversely with innate defenses (SIRT1, AGE receptor 1 [AGER1], glyoxalase-I, adiponectin). sAGEs correlated with dAGEs but not with calories, nutrient consumption, or fat mass measures. Consumption of dAGE, but not of calories, was markedly higher in MS than in non-MS.
conclusionHigh sAGEs, a modifiable risk factor for IR, may indicate risk for the MS, type 2 diabetes, and cardiovascular disease. High dietary AGE consumption and serum AGE levels may link healthy obesity to at-risk obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.